Multispecific Antibody Development Clinical Trials Sales Market Size Insight


More Than 600 Bispecific, Trispecific & Tetra Specific Antibodies Are In Clinical Trials Says Kuick Research In New Reports

Delhi, June 30, 2023 (GLOBE NEWSWIRE) — The development of multispecific antibodies, which have the potential to change the way cancer is treated, has been positively influenced by the commercial success of monoclonal antibodies in both the research and development fields. Multispecific antibodies are believed to take this a step further by being more target-specific due to their better structures. Monoclonal antibodies have showed superior anti-cancer effects compared to other treatments used to treat cancer. Bi-, tri-, and tetra-specific antibodies are currently the subject of research.

Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Companies & Market Trends Insight 2023 Report Highlights:


  • Global Tetraspecific Clinical Trials Landscape Insight
  • Global Tetraspecific Ongoing Clinical Trials By Company, Country, Indication & Phase
  • Tetraspecific Antibodies Proprietary Technologies By Company
  • Current Clinical Development & Future Commercialization Outlook
  • Tetraspecific Antibodies Mono & Combination Therapeutic Approaches
  • Competitive Landscape

Download Report:

Global Trispecific Antibody Market Opportunity & Clinical Trials Insight 2028 Analysis and Data Highlights:

  • Research Methodology
  • Global Market Analysis
  • Global Trispecific Antibody Market Opportunity Assessment: > USD 2 Billion
  • US To Dominate Trispecific Antibodies Market: >70%
  • Market and Drug Sales Insight 2024 Till 2028
  • Future Market Assessment By Indication Till 2028
  • Ongoing Clinical Trials Assessment by Status, Phase and Region
  • Key Market Dynamics
  • Competitor Landscape

Download Report:

Global Bispecific Antibody Market Opportunity & Clinical Trials Insight 2023 Report Highlights:

  • Yearly & Quarterly Sales Insight (2018 till Q1’2023)
  • Global & Regional Sales Insights
  • Global Market Forecast Till 2028
  • Approved Bispecific Antibodies: 9
  • Insight On Bispecific Antibodies In Clinical Trials: > 700 Bispecific Antibodies
  • Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase
  • Fast Track Approval, Orphan Designation & Priority Status Insights
  • Approved Bispecific Antibodies Pricing  & Dosage Analysis
  • Competitive Landscape: Top 50 Companies Developing Bispecific Antibodies

Download Report:

Nine bispecific antibodies have previously been made commercially available, six of which have received approval for the treatment of various malignancies, including both solid and hematologic ones. There are more than a hundred bispecific antibodies at various stages of research, and several are being studied in clinical studies. These are being developed by several prominent companies, including Roche, AstraZeneca, Akeso and Regeneron. Additionally, many hospitals and public health facilities are working with the developer companies to carry out these clinical trials. The US and China are the top two countries where the majority of these R&D activities are being carried out, according to the data given to the clinical trials database. Both of these countries share a number of beneficial characteristics that contribute to the robust and constant growth of the research and development segments.

After bispecific antibodies, researchers began working on the development of trispecific antibodies. As the name suggests, these have affinity for three targets, taking the specificity a step further from bispecific antibodies. Trispecific antibodies are being majorly developed as immune cell engaging antibodies, which helps reduce the time and gap between an immune cell and cancer cell. GT Biopharma, Numab, Harpoon Therapeutics and Janssen among some more pharmaceutical companies have trispecific antibodies currently in their clinical pipelines, all in early phases of development. A number of formats have been utilized to develop this newer class of drugs, giving them different mechanisms of action.

Other these, a third type of multispecific antibodies, called the tetraspecific antibodies, are being researched on but not as extensively as the other two. As the name suggests, they are designed to bind with four select targets, which makes them most target directed among all antibodies. While some tetraspecific antibodies have been developed, some others are being constructed as tetraspecific antibodies because of the limitations in designing their structure. In the R&D domain, Sichuan Baili Pharmaceutical and its US-based subsidiary Systimmune are leading with already three candidates in the pipeline. There is scanty information available about tetraspecific antibodies because very few researchers have been focusing on research activities regarding these.

In the recent years, a large number of people are getting diagnosed with cancer and a many of them are losing their lives to the dreaded disease. For long, cancer has burdened humans with financial and emotional stress because of which researchers are concerned with developing more and better therapeutic options. Monoclonal antibodies definitely paved the way for achieving this. With more resources and knowledge being shared within the cancer research domain, multispecific antibodies have now entered the clinical trials and some are also commercially available. Because of their targetability, they have been hailed as the next major treatment for cancer, especially when used in combination with other treatment modalities.  

All multispecific antibodies and the variety of formats which have been used to design these, make them better than monoclonal antibodies. While bispecific antibodies have already entered the market, trispecific and tetraspecific antibodies are still in their developmental phases and will take longer for them to be made available in the market. Multispecific antibodies provide a prospective option to change how cancer is treated in modern times and with support from different governments and organizations, can revolutionize the cancer treatment.  

CONTACT: Neeraj Chawla Kuick research Research Head [email protected]  

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.